S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:TARS

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

$34.57
+0.73 (+2.16%)
(As of 03/27/2024 ET)
Today's Range
$33.60
$35.05
50-Day Range
$22.84
$39.22
52-Week Range
$11.33
$40.40
Volume
410,039 shs
Average Volume
744,714 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.38

Tarsus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
39.9% Upside
$48.38 Price Target
Short Interest
Bearish
21.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Tarsus Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$749,578 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.59) to ($2.62) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

410th out of 939 stocks

Biological Products, Except Diagnostic Industry

62nd out of 156 stocks

TARS stock logo

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS Stock Price History

TARS Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
TARS Apr 2024 25.000 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
TARS Apr 2024 17.500 put
TARS Apr 2024 12.500 call
Tarsus Announces Proposed $100.0 Million Public Offering
See More Headlines
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TARS
Fax
N/A
Employees
244
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.38
High Stock Price Target
$59.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+39.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-135,890,000.00
Pretax Margin
-778.89%

Debt

Sales & Book Value

Annual Sales
$17.45 million
Book Value
$5.95 per share

Miscellaneous

Free Float
30,270,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
1.07
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Bobak R. Azamian M.D.
    Co-Founder, President, CEO & Chairman
  • Dr. Bryan Wahl J.D. (Age 46)
    M.D., General Counsel & Corporate Secretary
    Comp: $619.09k
  • Dr. Elizabeth Yeu Lin M.D. (Age 46)
    Chief Medical Advisor & Director
    Comp: $286k
  • Mr. Jeffrey S. Farrow (Age 62)
    CFO & Chief Strategy Officer
  • Dr. Seshadri Neervannan Ph.D. (Age 56)
    Chief Operating Officer
    Comp: $486.67k
  • Mr. David Nakasone
    Head of Investor Relations
  • Ms. Adrienne Kemp
    Senior Director of Corporate Communications
  • Mr. Matthew Rossen M.B.A. (Age 46)
    Vice President of Marketing
  • Mr. Scott Youmans
    Vice President of Sales
  • Ms. Dianne C. Whitfield M.S.W. (Age 47)
    Chief Human Resources Officer
    Comp: $578.9k

TARS Stock Analysis - Frequently Asked Questions

Should I buy or sell Tarsus Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TARS shares.
View TARS analyst ratings
or view top-rated stocks.

What is Tarsus Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 12 month price targets for Tarsus Pharmaceuticals' shares. Their TARS share price targets range from $30.00 to $59.00. On average, they anticipate the company's stock price to reach $48.38 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for TARS
or view top-rated stocks among Wall Street analysts.

How have TARS shares performed in 2024?

Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of the year. Since then, TARS shares have increased by 70.7% and is now trading at $34.57.
View the best growth stocks for 2024 here
.

When is Tarsus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our TARS earnings forecast
.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.06. The company had revenue of $13.08 million for the quarter, compared to analysts' expectations of $4.63 million. During the same period in the previous year, the company posted ($0.49) earnings per share.

What ETF holds Tarsus Pharmaceuticals' stock?

Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio.

When did Tarsus Pharmaceuticals IPO?

Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include RTW Investments LP (9.52%), Vivo Capital LLC (5.39%), Vanguard Group Inc. (4.82%), Vanguard Group Inc. (4.66%), TFG Asset Management GP Ltd (2.42%) and Dimensional Fund Advisors LP (1.30%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc.
View institutional ownership trends
.

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TARS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners